Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 911-919

  Esslinger, Hans Ulrich ^a   Haas, Sylvia ^b   Maurer, Robert ^a   Lassmann, Axel ^a   Dübbers, Katrin ^a   Müller Peltzer, Herbert ^a  

^a Knoll AG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ELLAGIC ACID; LEPIRUDIN; MACROGOL;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031010296     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656077     Document Type: Article

References (29)

1. Walsmann P, Markwardt F. On the isolation of the thrombin inhibitor hirudin. Thromb Res 1985; 40: 563-9.
2. Markwardt F, Hauptmann J, Nowak G, Kleßen Ch, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-9.
3. Ishikawa A, Hafter R, Seemüller U, Gokel JM, Graeff H. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC). Thromb Res 1980; 19: 351-8.
4. Rübsamen K, Eschenfelder V. Effect of recombinant hirudin (LU 52 369) on reocclusion rates after thrombolysis in rabbits. Haemostasis 1991; 21 (Suppl): 93-8.
5. Weitz JI, Califf R M, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. Chest 1995; 108 (4): 471S-85S
6. Eriksson BJ, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39 393. Lancet 1996; 347: 635-9.
7. Moia M, Schiele F, Walker M, Erikkson H, Camez A, Lemarie JC. Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-hirudin (HBW 023): a multicenter Study. Thromb Haemost 1995; 73(6): 1456.
8. Iyer L, Shavit J, Koza M, Calabria R, Moran S, Fareed J. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV 2-Lys 47) after repeated intravenous administration in dogs. Thromb Res 1993; 69: 59-70.
9. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23.
10. Esslinger H-U, Greger G, Lassmann A, Maurer R. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administration of recombinant hirudin (LU 52369) in man. Thromb Haemost 1991; 65 (6): 1291.
11. Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour. Biomed Biochim Acta 1990; 49: 1103-8.
12. Iorio A, Agnelli G, Leone M, Melelli P, Renga C, Nenci GG. Hirudin and PEG-Hirudin inhibit clot-bound thrombin more efficaciously than heparin. Ann Hematol 1993; 66 (Suppl I): 1818.
13. Hornberger W, Rübsamen K, Schweden J. Prolonged antithrombotic action of a new polyethyleneglycol-coupled hirudin (LU 57291) in two rat thrombosis models. Ann Hematol 1993; 66 (Suppl I): 20.
14. Laux V, Schweden J, Maurer R, Hornberger W, Rübsamen K. Antithrombotic effect of a new polyethyleneglycol-coupled hirudin (LU 57291) in a venous thrombosis model in the rabbit. Correlation with anti-factor IIa activity in plasma. Ann Hematol 1993; 66 (Suppl I): 27.
15. Rübsamen K, Hornberger W, Laux V, Schwarz M, Schweden J. Anti-thrombotic efficacy of the polyethyleneglycol-coupled hirudin mutein LU 57291 in experimentally induced venous and arterial thrombosis. Thromb Haemost 1993; 69: 2717.
16. Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70.
17. Kirchengast M, Rübsamen K. Prevention by PEG-Hirudin of platelet dependent thrombin formation in the stenosed, locally injured canine coronary artery. J Invasive Cardiol 1995; 7: 9C.
18. Walenga JM, Terrell MR, Koza MJ, Khenkina Y, Fareed J, Pifarré R. PEG-Hirudin as anticoagulant in cardiopulmonary bypass. Blood 1994; 84 (Suppl 1): 72.
19. Walenga JM, Terrell MR, Koza MJ, Khenkina Y, Fareed J, Pifarré R. PEG-Hirudin as anticoagulant in cardiopulmonary bypass. Thromb Haemost 1995; 73(6): 1454.
20. Zawilska K, Zozulinska M, Turowiecka Z, Blauhut M, Drobnik L, Vinazzer H. The effect of a long-acting recombinant hirudin (PEG-Hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993; 69: 315-20.
21. Rübsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-Hirudin and unfractionated heparin. Thromb Haemost 1996; 76 (1): 105-10.
22. Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagulation Fibrinolysis 1991; 2: 121-7.
23. Duke WW. The reaction of blood platelets to hemorrhagic disease. Description of a new method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic diseases relieved by transfusion. JAMA 1910; 55: 1185-92.
24. Mielke C, Kaneshiro M, Nahler J, Weiner J, Rapaport S. The standardised normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-15.
25. Thomann P. Non-Compartmental Analysis Methods Manual. In: TopFit: Version 2.0; pharmacokinetic and pharmacodynamic data analysis for the PC. Heinzel G, Woloszczak R, Thomann P, eds. Gustav Fischer Verlag, Stuttgart, Jena, New York 1993; (2): 5-66.
26. Aronson JK, Dengler HJ, Dettli L, Follath F. Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 1988; 35: 1-7.
27. Veng-Pedersen P, Gillespie WR. A polyexponential deconvolution method. Evaluation of the "gastrointestinal bioavailability" and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985; 13: 289-307.
28. Hornberger W, Kluge M, Rübsamen K. No evidence for rebound activation of platelets and coagulation after long-term administration of PEG-Hirudin (LU 57291) in rats. Ann Hematol 1994; 68 (Suppl II): A 100.
29. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70 (2): 286-8.